RE:RE:RE:RE:Stock priceAfter talking with the company this morning... I think more news is coming out very soon. I'm guessing it will be a deal with Genentech. We're on track to do 3 mil in CARA rev alone this year! That's major growth! The deal with DARC isn't a blockbuster in the sense of revenue but it does get us started with Regeneron. This is an important step, imo, because our contract with Regeneron gets us that much closer to Bayer, since they codeveloped Eylea. A deal with Bayer could send this stock much higher. I'm a little surprised that Genentech didn't come before Regeneron since Genentech is in bed with Novartis and Novartis has been aggressively utilizing CARA. Could it have something to do with Fovista? No question, digital imaging is the way of the future. Our technology has been validated by industry leaders so it's no longer a question of whether it can do the job. I think it is now about gathering sufficient data for each major (individually) as they did with Novartis so that they can make a decision based on their unique customer base and product. But hey... if they're willing to spend big bucks on making a decision to do it... then you know there's going to be big bucks generated in revenue if they decide to do it.